UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9.3% | 28.5% | 34% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 90.2% | 88.7% | 88.1% | 89.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -105.5% | -73% | -118.4% | -190.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -140.4% | -123.6% | -170.6% | -230.7% |
| EPS Diluted | -2.96 | -3.55 | -4.79 | -4.96 |
| % Growth | 16.6% | 25.9% | 3.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |